Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET
Company Participants
Bruce Mackle - LifeSci Advisors, IR
Dr. Steve Fruchtman - President and CEO
Dr. Victor Moyo - Consultant Chief Medical Officer
Mark Guerin - Chief Operating Officer and CFO
Fred Frullo - Vice President, Regulatory Affairs and Quality Assurance
Conference Call Participants
Edouard Mullarky - Guggenheim
Ahu Demir - Ladenburg Thalmann
Robert LeBoyer - Noble Capital Markets
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty]
Dr. Steve Fruchtman
Sarah, excuse me, you are coming in and out and I don’t know if other people hear. You coming in and out.
Operator
Thank you. Let me restart. Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. following management’s prepared remarks, we will hold a question-and-answer session. Operator
As a reminder, this call is being recorded today, August 10, 2023. At this time, I would like to turn the call over to Bruce Mackle of LifeSci Advisors. Go ahead.
Bruce Mackle
Thank you, Operator. And welcome everyone to Onconova’s second quarter 2023 financial results and business update conference call. Earlier this afternoon, Onconova issued a press release reporting its financial results and business progress. If you have not yet seen this press release, it is available in the Investors and Media section of the company’s website at www.onconova.com.
Following my introduction, we will hear from Onconova’s President and CEO, Dr. Steve Fruchtman; Consultant Chief Medical Officer, Dr. Victor Moyo; and Chief Operating Officer and Chief Financial Officer, Mark Guerin. Onconova’s VP of Regulatory Affairs and Quality Assurance, Fred Frullo, will also be available during the Q&A session following the prepared remarks.
Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, which involves risks and uncertainties that can cause actual results to differ materially.
Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward-looking statements, please review the disclaimer in today’s press release and the risk factors in the company’s SEC filings.